Predicting the response to therapy of inflammatory bowel disease with infrared spectroscopy

Predicting the response to therapy of inflammatory bowel disease with infrared spectroscopy - PROPHECY

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033130

Enrollment

1500

Registered

2023-12-04

Start date

2023-05-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K51 K50

Interventions

Group 1: Prospective real-world patient cohort initiating a novel line of therapy for ulcerative colitis: Analysis of routine large intestinal biopsies with infrared spectroscopy for artificial intell

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - established diagnosis of ulcerative colitis or Crohn's disease - diagnostic ileocolonoscopy with biopsies and subsequent initiation of a novel anti-inflammatory therapy

Exclusion criteria

Exclusion criteria: - drugs, concomitant diseases or conditions that preclude the assessment of clinical response/remission

Design outcomes

Primary

Measure	Time frame
Clinical remission week 16	—

Secondary

Measure	Time frame
Clinical remission week 52 Endoscopic remission week 52 Steroid-free remission week 52	—

Countries

Belgium, Germany, United States

Contacts

Public ContactSebastian Zundler

Universitätsklinikum Erlangen

sebastian.zundler@uk-erlangen.de+4991318535000

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026